Last reviewed · How we verify
BMB-101
BMB-101 is a small molecule that targets the S1P1 receptor.
BMB-101 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | BMB-101 |
|---|---|
| Sponsor | Bright Minds Biosciences Pty Ltd |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to the S1P1 receptor, BMB-101 modulates the sphingosine-1-phosphate (S1P) signaling pathway, which plays a crucial role in immune cell trafficking and lymphocyte egress from lymphoid organs.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome. (PHASE2)
- BMB-101 in Absence Epilepsy and DEE (PHASE2)
- A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMB-101 CI brief — competitive landscape report
- BMB-101 updates RSS · CI watch RSS
- Bright Minds Biosciences Pty Ltd portfolio CI